Table 2.
Multivariate analysis of survival according to pathological characteristics, TGF-β pathway, and TMB (cut-off 10%)
| DFSa |
OSa |
||||||
|---|---|---|---|---|---|---|---|
| Patients n (%) | HR | 95% CI (HR) | P value | HR | 95% CI (HR) | P value | |
| Total | 151 (100) | ||||||
| TMB (cut-off 10%) | 0.49 | 0.17-1.4 | 0.19 | 0.21 | 0.06-0.7 | 0.01 | |
| Low | 136 (90) | ||||||
| High | 15 (10) | ||||||
| AJCC stage | 1.90 | 1.33-2.7 | <0.001 | 1.37 | 1.07-1.8 | 0.01 | |
| Stage I | 20 (13) | ||||||
| Stage II | 36 (24) | ||||||
| Stage III | 30 (20) | ||||||
| Stage IV | 65 (43) | ||||||
| HPV | 0.42 | 0.06-3.1 | 0.40 | 0.56 | 0.14-2.3 | 0.43 | |
| Positive | 7 (5) | ||||||
| Negative | 144 (95) | ||||||
| Extranodal spreadb | 1.53 | 0.82-2.9 | 0.19 | 1.58 | 0.92-2.7 | 0.10 | |
| Negative | 111 (74) | ||||||
| Positive | 38 (26) | ||||||
| Invaded margins | 0.96 | 0.46-2.0 | 0.92 | 1.08 | 0.659-2.0 | 0.81 | |
| Negative | 127 (86) | ||||||
| Positive | 24 (16) | ||||||
| TGF-β pathway | 4.52 | 1.53-13.3 | 0.006 | 4.13 | 1.57-10.9 | 0.004 | |
| Unaltered | 6 (4) | ||||||
| Altered | 145 (96) | ||||||
95% CI, 95% confidence interval; AJCC, American Joint Committee on Cancer; DFS, disease-free survival; HPV, human papillomavirus; HR, hazard ratio; OS, overall survival; TGF-β, transforming growth factor-β; TMB, tumor mutational burden.
Significant values are indicated in bold.
a
Cox model.
b
Information available for 149 patients.